Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary

A Enjalbert and J Bockaert

In male and female rat anterior pituitary homogenates dopamine inhibited basal adenylate cyclase by 30% and 50%, respectively. Dopamine also inhibited vasoactive intestinal peptide-stimulated adenylate cyclase by 50% in both sexes. Sulpiride, a specific D2 antagonist, stereospecifically blocked with high affinity the dopamine inhibition in both males and females. RU 24926, a specific, non- catechol, non-ergot D2 agonist, also inhibited basal adenylate cyclase of female pituitary with a higher apparent affinity than dopamine (KDapp 20 nM and 450 nM, respectively). This effect was also stereospecifically antagonized by sulpiride. Apomorphine was also more potent (KDapp 100 nM) than dopamine, whereas norepinephrine and SKF 38393, a specific D1 agonist, were poorly active; isoproterenol and clonidine were inactive. Ergots derivatives such as CB 154, LY 14865, pergolide, and lergotrile were potent agonists. alpha- Dihydroergocryptine was a partial agonist of the dopamine receptor negatively coupled with an adenylate cyclase. Because of the slow association kinetics of this drug with the dopamine receptor, its KDapp (0.7 nM) for adenylate cyclase inhibition could be correctly determined only after a 30-min incubation period. All classical dopaminergic antagonists blocked dopamine inhibition of pituitary adenylate cyclase, pimozide (KI 1 nM) and spiperone (KI 0.8 nM) being the more potent. There were good correlations between the affinities of large series of agonists and antagonists for the anterior pituitary dopamine receptors negatively coupled with an adenylate cyclase on one hand, and for either D2 dopamine receptors labeled with [3H] dihydroergocryptine or [3H]spiroperidol in both pituitary and striatum, or D2 pituitary receptors involved in prolactin secretion on the other hand. It is concluded that the pituitary dopamine receptors negatively coupled with an adenylate cyclase are the classical D2 receptors involved in prolactin secretion.

Volume 23, Issue 3, pp. 576-584, 05/01/1983
Copyright © 1983 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				A. E. Gonzalez-Iglesias, T. Murano, S. Li, M. Tomic, and S. S. Stojilkovic Dopamine Inhibits Basal Prolactin Release in Pituitary Lactotrophs through Pertussis Toxin-Sensitive and -Insensitive Signaling Pathways Endocrinology, April 1, 2008; 149(4): 1470 - 1479. [Abstract] [Full Text] [PDF]

				P. Fitzgerald and T. G Dinan Prolactin and dopamine: What is the connection? A Review Article J Psychopharmacol, March 1, 2008; 22(2_suppl): 12 - 19. [Abstract] [PDF]

				M. C. Zatelli, M. R. Ambrosio, M. Bondanelli, and E. C d. Uberti Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds Eur. J. Endocrinol., April 1, 2007; 156(suppl_1): S29 - S35. [Abstract] [Full Text] [PDF]

				J.-M. Beaulieu, E. Tirotta, T. D. Sotnikova, B. Masri, A. Salahpour, R. R. Gainetdinov, E. Borrelli, and M. G. Caron Regulation of Akt Signaling by D2 and D3 Dopamine Receptors In Vivo J. Neurosci., January 24, 2007; 27(4): 881 - 885. [Abstract] [Full Text] [PDF]

				M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]

				S. Glaser, D. Alvaro, T. Roskams, J. L. Phinizy, G. Stoica, H. Francis, Y. Ueno, B. Barbaro, M. Marzioni, J. Mauldin, et al. Dopaminergic inhibition of secretin-stimulated choleresis by increased PKC-gamma expression and decrease of PKA activity Am J Physiol Gastrointest Liver Physiol, April 1, 2003; 284(4): G683 - G694. [Abstract] [Full Text] [PDF]

				M. G. Hearn, Y. Ren, E. W. McBride, I. Reveillaud, M. Beinborn, and A. S. Kopin A Drosophila dopamine 2-like receptor: Molecular characterization and identification of multiple alternatively spliced variants PNAS, October 29, 2002; 99(22): 14554 - 14559. [Abstract] [Full Text] [PDF]

				J. D. Kilts, H. S. Connery, E. G. Arrington, M. M. Lewis, C. P. Lawler, G. S. Oxford, K. L. O'Malley, R. D. Todd, B. L. Blake, D. E. Nichols, et al. Functional Selectivity of Dopamine Receptor Agonists. II. Actions of Dihydrexidine in D2L Receptor-Transfected MN9D Cells and Pituitary Lactotrophs J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 1179 - 1189. [Abstract] [Full Text] [PDF]

				A. Ozawa, M. Yamada, T. Satoh, T. Monden, K. Hashimoto, H. Kohga, Y. Hashiba, T. Sasaki, and M. Mori Transcriptional Regulation of the Human PRL-Releasing Peptide (PrRP) Receptor Gene by a Dopamine 2 Receptor Agonist: Cloning and Characterization of the Human PrRP Receptor Gene and Its Promoter Region Mol. Endocrinol., April 1, 2002; 16(4): 785 - 798. [Abstract] [Full Text] [PDF]

				T. Sato, M. M. Meguid, S. O. Fetissov, C. Chen, and L. Zhang Hypothalamic dopaminergic receptor expressions in anorexia of tumor-bearing rats Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2001; 281(6): R1907 - R1916. [Abstract] [Full Text] [PDF]

				K. A. Gregerson, T. P. Flagg, T. J. O'Neill, M. Anderson, O. Lauring, J. S. Horel, and P. A. Welling Identification of G Protein-Coupled, Inward Rectifier Potassium Channel Gene Products from the Rat Anterior Pituitary Gland Endocrinology, July 1, 2001; 142(7): 2820 - 2832. [Abstract] [Full Text] [PDF]

				M. E. Freeman, B. Kanyicska, A. Lerant, and G. Nagy Prolactin: Structure, Function, and Regulation of Secretion Physiol Rev, October 1, 2000; 80(4): 1523 - 1631. [Abstract] [Full Text] [PDF]

				J. Kim, Jür. Wess, A. M. v. Rhee, T. Schöneberg, and K. A. Jacobson Site-directed Mutagenesis Identifies Residues Involved in Ligand Recognition in the Human A[IMAGE] Adenosine Receptor J. Biol. Chem., June 9, 1995; 270(23): 13987 - 13997. [Abstract] [Full Text] [PDF]